Single-cell multi-omics data reveal heterogeneity in liver tissue microenvironment induced by hypertension [0.03%]
单细胞多组学数据揭示了高血压诱导的肝组织微环境异质性
Hongfei Li,Lingyu Cui,Murong Zhou et al.
Hongfei Li et al.
Hypertension (HTN) may induce liver damage; however, the effects on liver cell subpopulations remain obscure. Understanding these microenvironmental changes could offer early HTN and liver disease indicators. We employed single-cell multi-o...
Antisense oligonucleotide-mediated upregulation of Jag1 ameliorates liver disease phenotypes in a mouse model of Alagille syndrome [0.03%]
反义寡核苷酸介导的Jag1上调改善Alagille综合征小鼠模型的肝病表型
Lingdi Zhang,Nima Niknejad,Jian Li et al.
Lingdi Zhang et al.
Alagille syndrome (ALGS) is a rare genetic disorder that affects multiple organ systems, especially the liver, leading to life-threatening complications. In most cases, ALGS is caused by haploinsufficient mutations in the JAG1 gene, resulti...
Olivia Kovecses,Bahram Sharif-Askari,Cristobal Gonzalez-Losada et al.
Olivia Kovecses et al.
[This corrects the article DOI: 10.1016/j.omtn.2025.102611.]. © 2025 The Author(s).
Published Erratum
Molecular therapy. Nucleic acids. 2025 Aug 20;36(3):102643. DOI:10.1016/j.omtn.2025.102643 2025
Nose-to-brain siRNA delivery by PEI/PPI-based nanoparticles reduces α-synuclein expression in a Parkinson's disease mouse model [0.03%]
基于PEI/PPI的纳米颗粒介导的针对帕金森病小鼠模型的鼻脑siRNA递送降低α-突触核蛋白表达
Malte Feja,Isabell Drath,Sandra Weiß et al.
Malte Feja et al.
Potential strategies to develop new treatments for Parkinson's disease (PD) aim at targeting disease-associated proteins like alpha-synuclein (aSyn), which accumulates in neurons of PD patients and contributes to neuronal degeneration. A pr...
Targeting long non-coding RNA MALAT1 preserves endothelial cell integrity and protects against kidney fibrosis [0.03%]
靶向长链非编码RNA MALAT1可维护内皮细胞的完整性并保护肾脏免受纤维化损害
Qiao Zhao,Loïs A K van der Pluijm,Morgane Gourvest et al.
Qiao Zhao et al.
Loss of integrity of the capillary network is directly associated with the development of kidney fibrosis resulting in chronic kidney disease. Here, we characterized long non-coding RNAs (lncRNAs) in endothelial cells (ECs) during the devel...
The circITSN1/eIF4A3/Itsn1 axis, a potential new molecular entry point for managing postoperative cognitive dysfunction [0.03%]
circITSN1/eIF4A3/Itsn1轴可能是干预术后认知功能障碍的一个新的分子切入点
Sedef Ersoy,Christian Bär
Sedef Ersoy
Manipulating the delivery and immunogenicity of DNA vaccines through the addition of CB[8] to cationic polymers [0.03%]
通过向阳离子聚合物中添加CB[8]来操纵DNA疫苗的递送和免疫原性
Hadijatou J Sallah,Benjamin T Cheesman,David J Peeler et al.
Hadijatou J Sallah et al.
Challenges with vaccine reactogenicity, stability, and access have highlighted the need to develop alternative strategies for formulation and delivery. We explored the incorporation of cucurbit[n]urils (CBs), as supramolecular "hosts," into...
The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases [0.03%]
Circular RNA在新兴传染病疫苗和药物开发中的潜力与挑战
Keda Chen,Yutong Xu,Jiaxuan Li et al.
Keda Chen et al.
Circular RNAs (circRNAs) are a class of RNA molecules with a covalent closed-loop structure that play important roles in the regulation of biological processes and disease genesis. In recent years, circRNAs have become a research hotspot du...
Molecular treatment options for patients carrying KIAA0586/TALPID3 variants [0.03%]
携带KIAA0586/TALPID3变异患者的分子治疗选项
Jacqueline E Taudien,Sebastian Swirski,Maike Möller et al.
Jacqueline E Taudien et al.
Variants in KIAA0586/TALPID3 are associated with the ciliopathy Joubert syndrome (JS), which is a genetically heterogeneous disorder. Mutations in more than 40 different genes were associated with JS, genes that are relevant to ciliary asse...
Pharmacometric modeling of lipid nanoparticle-encapsulated mRNA therapeutics and vaccines: A systematic review [0.03%]
脂质纳米颗粒包封的mRNA治疗和疫苗的药代动力学建模：系统性综述
Miao Zhang,Linh Van,Mansoor M Amiji
Miao Zhang
Significant progress has been made in the development of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA)-based modalities with numerous candidates entering clinical trials. These novel modalities require the application of innova...